Open Clinical Trials
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Nancy Brunetti
Title: A Safety And Efficacy Trial Evaluating The Use Of Apixaban In The Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism.
Diagnoses: Deep Vein Thrombosis or Pulmonary Embolism
Study Inclusion Criteria:
- Male or female 18 years or older
- Patients presenting with new onset of DVT and PE
This research study has been reviewed and approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12262.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12262.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Thomas Parsons
Title: A randomized, double blind, placebo controlled study evaluating the efficacy & safety of romiplostim treatment of thrombocytopenia in subjects with low or intermediate-1 risk Myelodysplastic Syndrome (MDS). Amgen.
Diagnoses: Low or intermediate risk myelodysplastic syndrome
Study Inclusion Criteria:
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #11782.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #11782.
Principal Investigator: S. Asim Ali, MD
Primary Contact: Thomas Parsons
Title: A phase III, randomized, double blind, placebo controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC).
Diagnoses: Metastatic non-small cell lung cancer
Study Inclusion Criteria:
- Patients who have progressed after first treatment
- Fulfill all other eligibility criteria
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12087.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12087.
Principal Investigator: Michael E. Bromberg, MD, PhD
Primary Contact: Thomas Parsons
Title: A Phase 2, Mulitcenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantle Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib.
Diagnoses: Mantle Cell Lymphoma
Study Inclusion Criteria:
- Disease progressed after treatment
- Fulfill all other eligibility criteria
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12064.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12064.
Principal Investigator: Aruna Padmanabhan, MD
Primary Contact: Nancy Brunetti
Title: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment of ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer.
Diagnoses: Locally Recurrent or Metastatic Breast Cancer
Study Inclusion Criteria:
- Breast cancer that is not treatable by surgery and/or radiation
- Fulfill all other eligibility criteria
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12613.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12613.
Principal Investigator: Aruna Padmanabhan, MD
Primary Contact: Nancy Brunetti
Title: A Randomized, double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
Diagnoses: Early-Stage Breast Cancer
Study Inclusion Criteria:
- Positive for a specific protein in the cancer
- Fulfill all other eligibility criteria
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12610.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12610.
Principal Investigator: Deric S. Savior, MD
Primary Contact: Thomas Parsons
Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer.
Diagnoses: Non-Small Cell Lung Cancer
Study Inclusion Criteria:
- Undergo surgery for Lung resection
- Positive for a specific gene in the cancer cells
- Fulfill all other eligibility criteria
This research study has been reviewed and is approved by the Temple University Institutional Review Board and is assigned IRB Protocol #12983.
If you wish to be contacted regarding this study, please email cancer@tuhs.temple.edu and refer to study #12983.
For more information about these or any other clinical trials available at the Temple Cancer Center, please call the Research Office at 215-707-9433.
TOP